AstraZeneca and Pozen sue Dr Reddy's over Vimovo patent

27 April 2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN and USA-based Pozen (Nasdaq; POZN) have filed a law suit against India headquartered Dr Reddy’s Laboratories (NYSE: RDY) in the US District Court for the District of New Jersey, for infringement of US Patent No. 6,926,907 relating to Vimovo (naproxen/esomeprazole magnesium) delayed-release tablets.

The FDA last year approved Vimovo for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers, triggering a $20 million milestone payment to Pozen (The Pharma Letter May 4, 2010).

Drug has significant earnings potential for Pozen

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK